OKG Capital: Investment Portfolio & Startup News
OKG Capital
To add a bio or update investment portfolio click update information.
Investment Portfolio
52North raises £3.2m in funding led by Macmillan Cancer Support to support urgent cancer care diagnostics
52North is a medical technology spin-out from the University of Cambridge developing the Aster biomarker platform and Neutrocheck, a rapid finger-prick blood test. Neutrocheck supports remote triaging of chemotherapy patients at risk of neutropenic sepsis to reduce unnecessary emergency hospital visits.
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
Oncology medical tech startup 52North secures £5m with landmark UK-US hospital VC deal
52North builds medical devices and digital tools that support cancer patients outside hospital, focusing on early detection and monitoring of treatment-related complications to improve urgent oncology care pathways.
- 1(12 months)
- okgcapital.com
More venture news
- 10 Nov 2026
AncepAncep raises £6m in funding led by Creandum to help insurance brokers cover the clients they’d normally turn down
EquityEnterprise - 9 Nov 2026
Crowd ThreatCrowd Threat lands £1m in funding from Mercia Ventures and PXN Group to track global security risks through local reports
EquityDefence - 27 Oct 2026
LuthmoreLuthmore secures £5m from the FSE Group to roll out its battery-powered zero-emissions boiler
EquityIndustrial
